Hernia, Ventral

Anovo robotic surgical platform is the world's first single port robotics platform approved for ventral hernia repairs in the US TEL AVIV, Israel and FORT LAUDERDALE, Fla., Oct. 15, 2024 /PRNewswire/ -- Momentis Surgical Ltd., a medical device company dedicated to transforming robot-assisted surgery with its proprietary technology, today announced that the U.S. Food and Drug Administration (FDA) has granted 510(k) Clearance to its Anovo™ robotic surgical platform for use in single site, abdominal access ventral hernia repair. The FDA clearance announced today complements the system's existing approvals in natural orifice laparoscopic-assisted transvaginal benign gynecology surgical procedures. Continue Reading Anovo's flexible robotic arms Dvir Cohen, CEO and Co-Founder of Momentis Surgical, said, "Leveraging the clinical achievements of our Anovo platform in gynecology and the connections we established with leading medical centers worldwide, we have seized the opportunity to expand to general surgery for our groundbreaking technology. Due to its size and mobility, our system can be used both in hospitals and outpatient settings, where most hernia surgeries can be performed, but are not currently, because of the limitations of existing robotic platforms. Anovo's unique features allow surgeons and patients access to robotic procedures outside the hospital by offering robotic technology to ambulatory surgical centers." Anovo is the world's first single port robotics platform approved by the FDA to perform ventral hernia procedures. Performing procedures through a single port with multiple flexible instruments has the potential to result in less invasive and less traumatic outcomes for the tissue at the point of entry, enabled by the small portable robotic system. The Anovo system is the first and only FDA-authorized surgical robotic platform that features miniature humanoid-shaped robotic arms that provide human level dexterity, multi-planar flexibility and 360 degrees of articulation. The biomimetic instruments are designed to replicate the motions and capabilities of a surgeon's arms, with shoulder, elbow and wrist joints. Multiple instruments can be introduced to the body through a single portal and the 360-degree articulation offers obstacle avoidance as well as optimal access and working angles. "This FDA authorization represents a significant advancement in the world of robotic surgery by making Anovo a versatile robotics platform for multi-specialty use," said Professor Tim Tollens, MD, Head of Surgery at Imelda Hospital in Bonheiden, Belgium, who performed a series of ventral hernia procedures using the Anovo system. "I have experience with other robotic systems and the Anovo platform is not only potentially better for my patients by reducing the number of incisions, but also incredibly easy for me and my OR staff to use. The average docking time for the robot was under 2 minutes, which is an order of magnitude faster than other robotic systems." Frederic H. Moll, M.D., Momentis board member and founder of Intuitive Surgical and Auris Health, added, "I have spent my career developing groundbreaking surgical robotic technology and I believe the future of soft tissue robotics is flexible instruments. I am very impressed with what the Momentis team has achieved to date. As the company has now created a true robotics platform, this technology is clearly differentiating and will have an immediate impact on the way general surgery is performed as it has in gynecology." "We are thrilled with adding a very high-volume surgical procedure to the approved indications for Anovo," said Maurice R Ferré, MD, Chairman of Momentis Surgical, Chairman and CEO of Insightec and Co-Founder and former CEO of MAKO Surgical. "This is only the beginning of the impact this single port, flexible robotics platform will have on robotic surgery." About Momentis Surgical™ Momentis Surgical is dedicated to transforming the field of robotic surgery by developing innovative small footprint, cost-effective, robotic-assisted technologies and techniques for a growing number of clinical applications. Our goal is to empower surgeons to perform minimally invasive, complex procedures, enabling better patient outcomes, lowering cost of care, and opening access to surgical robotics to more surgeons, patients, hospitals, and surgery centers across the globe. For more information, visit: . Media Contact: Tsipi Haitovsky Global Media Liaison +972-525-989892 [email protected] Photo - SOURCE Momentis Surgical WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

BRONX, N.Y., July 29, 2024 /PRNewswire/ -- Prominently featured in The Inner Circle, Joseph Vazzana is acknowledged as a Pinnacle Life Healthcare Professional for his contributions to the field of Gastrointestinal Surgery. Continue Reading Joseph Thomas Vazzana, MD Dr. Vazzana pursued higher education at New York University where he earned a Bachelor of Science degree in Neuroscience and Psychology, minoring in Chemistry. He then attended S.U.N.Y Downstate Medical Center in Brooklyn where he received a medical degree. The doctor completed a general surgical residency at the University of Buffalo; a research fellowship in immunology and vaccination strategies for the treatment of cancer at Roswell Park Cancer Institute in Buffalo, New York; and a fellowship in minimally invasive surgery/advanced gastrointestinal surgery at Montefiore Medical Center. Dr. Vazzana is board-certified in general surgery by the American Board of Surgery (ABS) and explained that the ABS is an independent, non-profit organization located in Philadelphia, Pennsylvania, founded for the purpose of certifying surgeons who have met a defined standard of education, training, and knowledge. The doctor works within the Department of Surgery at the Montefiore Medical Center as a general surgeon and notes that it is the premier academic medical center and the primary teaching hospital of the Albert Einstein College of Medicine in the Bronx, New York City. He specializes in bariatric/foregut surgery; abdominal wall hernia repair; and colorectal surgeries and is affiliated with Montefiore Weiler Hospital; Montefiore Greene Medical Arts Pavilion; Montefiore at 1250 Waters Place; Montefiore Wakefield Campus; St. Johns Riverside Hospital Dobbs Ferry; St. Johns Riverside Hospital; and St. Johns Riverside Boyce. The doctor is highly sought after for his vast knowledge of the field and serves as an Assistant Professor within the Department of Surgery at the Albert Einstein College of Medicine, Jack and Pearl Resnick Campus. He said that general surgery is a surgical specialty that focuses on abdominal contents including the esophagus; stomach; small bowel; colon; liver; pancreas; gallbladder; appendix and bile ducts; and often the thyroid gland. As a general surgeon, Dr. Vazzana performs a wide range of abdominal surgeries for many forms of intestinal and abdominal wall neoplasms; gallbladder disease; and gastric and pancreatic disease and follows the patient through critical care and surgical recovery all the way to outpatient care. His expertise in weight reduction surgery as well as minimally invasive approaches to complex surgical disease allow him to treat the entirety of the obese surgical patient. He stated, "The obesity epidemic is growing not just in the United states but across the globe. We as surgeons need to utilize all of the tools at our disposal to handle these complex patients." His practice focuses on weight reduction surgery as a means to accomplish excellent outcomes in the morbidly obese patient across multiple general surgery conditions including but not limited to abdominal wall reconstruction (hernia repair) and colorectal surgery. Dedicated to provide the latest innovations in the field, Dr. Vazzana is a Fellow of the American College of Surgeons, American Society for Metabolic and Bariatric Surgery, and a member of the Society of Gastrointestinal Surgery. While reflecting on his career, the doctor attributes much of his success to his mentors, Norman Sas, MD; William Scott Melvin, MD; Diego Cammacho, MD; and Anibal Puente, MD. Contact: Katherine Green, 516-825-5634, [email protected] SOURCE The Inner Circle

MOUNTAIN VIEW, Calif., Jan. 24, 2024 (GLOBE NEWSWIRE) -- AbSolutions Med, Inc., a privately held medical device company, announced today that the Food and Drug Administration (FDA) has granted Breakthrough Device Designation for its REBUILD Bioabsorbable (“REBUILD”) abdominal wall closure device. REBUILD met the criteria set by the FDA for Breakthrough Devices, potentially providing a novel treatment of an often irreversibly debilitating condition: incisional hernia. Less than 7% of Breakthrough Devices are in the field of general surgery, making REBUILD a standout product in a sector of medicine struggling to make profound advances. Since the first documented laparotomy in 1809, general surgery has been challenged by its limitations in reliably managing a basic but fundamental aspect of abdominal surgery – closure of the abdominal wall. Clinical failure of the closure from sutures tearing through tissue leads to incisional hernia in up to 35.6% of cases1. The impact of a failed abdominal closure can be devastating, with lifelong debilitation, morbidity, and re-operation occurring in a large percentage of patients. REBUILD supports the abdominal wall closure by distributing suture tension over a large area of tissue to maintain apposition of the midline fascial structures during the critical period of healing after surgery, and is then absorbed so as to minimize the risk of long-term foreign body complications. REBUILD has been tested in both animal and human studies with promising outcomes. “The field of hernia repair and hernia prevention has been dominated exclusively by various mesh products. REBUILD takes a different approach, focusing on the root cause of the problem by supporting intrinsic tissue healing, designed to eliminate long-term foreign bodies, and potentially improving patient quality of life by breaking the vicious cycle of repairs, complications and re-operations,” said Dr. Daniel Jacobs, CEO of AbSolutions Med, Inc. About REBUILD REBUILD is intended to support soft tissue approximation of the abdominal wall in conjunction with suture by distributing tension to maintain apposition of the rectus muscles during healing, which has been associated with reduction in post-operative ventral hernia formation. REBUILD is not cleared by the FDA and is not for sale. About AbSolutions Med, Inc. AbSolutions Med, Inc. is a medical device company with the vision to move beyond mesh and rebuild abdominal wall integrity while maintaining normal anatomy and function. For more information, please contact info@absolutionsmed.com or call 1-833-4-ABSMED (1-833-422-7633). 1 Bosanquet DC, Ansell J, Abdelrahman T, Cornish J, … Torkington J (2015) Systematic Review and Meta-Regression of Factors Affecting Midline Incisional Hernia Rates: Analysis of 14,618 Patients. PLoS ONE 10(9): e0138745. DOI: 10.1371/journal.pone.0138745